Methods for the analysis of histone H3 and H4 acetylation in blood

References

• Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005; 102:3697 - 702; http://dx.doi.org/10.1073/pnas.0500369102; PMID: 15738394
   PubMed Web of Science ®Google Scholar
• Lindemann RK, Gabrielli B, Johnstone RW. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 2004; 3:779 - 88; http://dx.doi.org/10.4161/cc.3.6.927; PMID: 15153801
   PubMed Web of Science ®Google Scholar
• Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 2001; 7:971 - 6; PMID: 11309348
   PubMed Web of Science ®Google Scholar
• Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, et al. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res 2002; 62:6108 - 15; PMID: 12414635
   PubMed Web of Science ®Google Scholar
• Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010; 3:5; http://dx.doi.org/10.1186/1756-8722-3-5; PMID: 20132536
   PubMed Web of Science ®Google Scholar
• Maiso P, Carvajal-Vergara X, Ocio EM, López-Pérez R, Mateo G, Gutiérrez N, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006; 66:5781 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-05-4186; PMID: 16740717
   PubMed Web of Science ®Google Scholar
• Kim IA, Kim IH, Kim HJ, Chie EK, Kim JS. HDAC inhibitor-mediated radiosensitization in human carcinoma cells: a general phenomenon?. J Radiat Res 2010; 51:257 - 63; http://dx.doi.org/10.1269/jrr.09115; PMID: 20505264
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12:1247 - 52; http://dx.doi.org/10.1634/theoncologist.12-10-1247; PMID: 17962618
   PubMed Web of Science ®Google Scholar
• Bertino EM, Otterson GA. Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs 2011; 20:1151 - 8; http://dx.doi.org/10.1517/13543784.2011.594437; PMID: 21699444
   PubMed Web of Science ®Google Scholar
• Ronzoni S, Faretta M, Ballarini M, Pelicci P, Minucci S. New method to detect histone acetylation levels by flow cytometry. Cytometry A 2005; 66:52 - 61; http://dx.doi.org/10.1002/cyto.a.20151; PMID: 15915507
   PubMed Web of Science ®Google Scholar
• Wiktorowicz JE, Bonner J. Studies on histone acetyltransferase. Partial purification and basic properties. J Biol Chem 1982; 257:12893 - 900; PMID: 7130185
   PubMed Web of Science ®Google Scholar
• Sureda. A, Younes A, Ben-Yehuda D, Ong T-C, Kaufman JL, Le Corre C et al. Final analysis: Phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem cell transplant. 52nd ASH Annual Meeting and Exposition, 2010; Abstract 419.
   Google Scholar
• Hamberg P, Woo MM, Chen LC, Verweij J, Porro MG, Zhao L, et al. Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol 2011; 68:805 - 13; http://dx.doi.org/10.1007/s00280-011-1693-x; PMID: 21706316
   PubMed Web of Science ®Google Scholar
• Dashwood RH, Ho E. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol 2007; 17:363 - 9; http://dx.doi.org/10.1016/j.semcancer.2007.04.001; PMID: 17555985
   PubMed Web of Science ®Google Scholar
• Kelly WK, O’Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23:3923 - 31; http://dx.doi.org/10.1200/JCO.2005.14.167; PMID: 15897550
   PubMed Web of Science ®Google Scholar
• Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006; 12:4628 - 35; http://dx.doi.org/10.1158/1078-0432.CCR-06-0511; PMID: 16899611
   PubMed Web of Science ®Google Scholar
• Dahl JA, Collas P. Q2ChIP, a quick and quantitative chromatin immunoprecipitation assay, unravels epigenetic dynamics of developmentally regulated genes in human carcinoma cells. Stem Cells 2007; 25:1037 - 46; http://dx.doi.org/10.1634/stemcells.2006-0430; PMID: 17272500
   PubMed Web of Science ®Google Scholar
• Johnson DT, Harris RA, French S, Blair PV, You J, Bemis KG, et al. Tissue heterogeneity of the mammalian mitochondrial proteome. Am J Physiol Cell Physiol 2007; 292:C689 - 97; http://dx.doi.org/10.1152/ajpcell.00108.2006; PMID: 16928776
   PubMed Web of Science ®Google Scholar
• Köhler A, Hurt E. Gene regulation by nucleoporins and links to cancer. Mol Cell 2010; 38:6 - 15; http://dx.doi.org/10.1016/j.molcel.2010.01.040; PMID: 20385085
   PubMed Web of Science ®Google Scholar
• Cremer M, von Hase J, Volm T, Brero A, Kreth G, Walter J, et al. Non-random radial higher-order chromatin arrangements in nuclei of diploid human cells. Chromosome Res 2001; 9:541 - 67; http://dx.doi.org/10.1023/A:1012495201697; PMID: 11721953
   PubMed Web of Science ®Google Scholar
• Boyle S, Gilchrist S, Bridger JM, Mahy NL, Ellis JA, Bickmore WA. The spatial organization of human chromosomes within the nuclei of normal and emerin-mutant cells. Hum Mol Genet 2001; 10:211 - 9; http://dx.doi.org/10.1093/hmg/10.3.211; PMID: 11159939
   PubMed Web of Science ®Google Scholar
• Croft JA, Bridger JM, Boyle S, Perry P, Teague P, Bickmore WA. Differences in the localization and morphology of chromosomes in the human nucleus. J Cell Biol 1999; 145:1119 - 31; http://dx.doi.org/10.1083/jcb.145.6.1119; PMID: 10366586
   PubMed Web of Science ®Google Scholar
• Tumbar T, Sudlow G, Belmont AS. Large-scale chromatin unfolding and remodeling induced by VP16 acidic activation domain. J Cell Biol 1999; 145:1341 - 54; http://dx.doi.org/10.1083/jcb.145.7.1341; PMID: 10385516
   PubMed Web of Science ®Google Scholar
• Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 2007; 76:75 - 100; http://dx.doi.org/10.1146/annurev.biochem.76.052705.162114; PMID: 17362198
   PubMed Web of Science ®Google Scholar
• Vettese-Dadey M, Grant PA, Hebbes TR, Crane- Robinson C, Allis CD, Workman JL. Acetylation of histone H4 plays a primary role in enhancing transcription factor binding to nucleosomal DNA in vitro. EMBO J 1996; 15:2508 - 18; PMID: 8665858
   PubMed Web of Science ®Google Scholar
• Yan C, Boyd DD. Histone H3 acetylation and H3 K4 methylation define distinct chromatin regions permissive for transgene expression. Mol Cell Biol 2006; 26:6357 - 71; http://dx.doi.org/10.1128/MCB.00311-06; PMID: 16914722
   PubMed Web of Science ®Google Scholar